Status:
COMPLETED
A Pharmacy-based Observational Study to Learn More About Iberogast Advance in the Real-world Setting
Lead Sponsor:
Bayer
Conditions:
Functional Gastrointestinal Disorders Such as Irritable Bowel Syndrome and Functional Dyspepsia
Irritable Bowel Syndrome
Eligibility:
All Genders
18+ years
Brief Summary
This is an observational study in which data from people with functional gastrointestinal disorders who decide on their own or by recommendation of their doctors or pharmacists to take Iberogast Advan...
Eligibility Criteria
Inclusion
- Adult female or male subject aged ≥ 18
- Decision to initiate treatment with Iberogast Advance was made as per pharmacist's routine recommendation practice/by the subject
- Subject purchases Iberogast Advance for his own use
- Not pregnant or lactating
- Not hypersensitive to any of the ingredients of Iberogast Advance
Exclusion
- Patients with known hypersensitivity to any of the ingredients of Iberogast Advance
- Pregnant or lactating women
Key Trial Info
Start Date :
June 4 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 11 2023
Estimated Enrollment :
184 Patients enrolled
Trial Details
Trial ID
NCT05389709
Start Date
June 4 2022
End Date
May 11 2023
Last Update
December 26 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Many Locations
Multiple Locations, Many Locations, Germany